Revvity (RVTY) Q1 2026 Earnings Transcript

Revvity reported Q1 revenue of $711 million, with adjusted EPS of $1.06 beating the $1.02-$1.04 guide and adjusted operating margin at 23.6% versus 23% expected. On a pro forma basis excluding China immunodiagnostics, organic growth was 6% and margin was 24%, while full-year 2026 guidance was reaffirmed/raised to 3%-4% organic growth, 28.4% margin, and $5.20-$5.30 EPS. Management also announced a strategic divestiture of the China immunodiagnostics business, alongside $86 million of share repurchases and continued AI/software product launches.

Analysis

RVTY is using the China immunodiagnostics exit to convert a low-quality revenue stream into cleaner optics, higher margin, and better capital allocation optionality. The key second-order effect is that management is no longer forced to defend a structurally impaired subscale business, which should improve execution discipline across the rest of the portfolio and reduce the probability of future negative surprises from APAC diagnostics pricing. The market should treat the divestiture less as a one-off earnings haircut and more as a de-risking event that raises the credibility of the long-range plan.

The bigger upside driver is that the company’s mix is shifting toward businesses where software, instruments, and reagents reinforce each other. That creates a more durable flywheel: AI-driven discovery increases experimental throughput, which lifts consumables and high-content systems, while software ARR gives management a higher-quality recurring anchor. If that loop starts to show up in the next 2-3 quarters, the valuation multiple can expand even if headline organic growth stays only mid-single digits.

The main risk is that the stock may have already priced in a lot of the strategic improvement before the cash benefits actually arrive. The transaction won’t close until 2027, so near-term EPS optics improve faster than cash proceeds, and any stumble in pharma/biotech or software comp cadence could expose the guide as conservative rather than beatable. The underappreciated variable is buyback intensity: if management uses the next 12 months to retire stock aggressively, per-share upside could outpace operating growth, making this more of a capital-return story than a pure top-line re-rating.

Consensus may be underestimating how much of the earnings-quality improvement is permanent. Ex-China, the business is not just smaller; it is more visible, less cyclical, and less management-intensive, which should compress the discount applied to the diagnostics franchise. The market likely focuses on the 2026 EPS bridge, but the real setup is 2027 when cost actions annualize, the mix is cleaner, and buybacks can be layered onto a higher-quality base.

Key Decisions for Investors

• Long RVTY on a 3-6 month horizon: use any post-rally consolidation to build a position; risk/reward improves if the stock trades at a discount to peers despite cleaner pro forma margins and a de-risked China profile.
• Pair trade: long RVTY / short a China-exposed diagnostics or tools name for 1-2 quarters; thesis is that RVTY’s portfolio cleanup and buyback capacity should outperform businesses still trapped in policy-driven APAC headwinds.
• Buy RVTY calls into the next catalyst window around Investor Day in November 2026; the setup is for software and AI monetization to re-rate the multiple if management can show a credible 2027 margin step-up.
• If already long, hedge with short-dated puts around quarterly prints; the stock is vulnerable to any softening in software cadence or pharma/biotech order commentary because the market is leaning on an improving narrative.
• Monitor share repurchase pace closely; if management continues aggressive buybacks through 2H26, add on dips because per-share EPS accretion could become the dominant upside driver ahead of divestiture close.